Recent 8-K filings for ANEB

• February 12, 2026, 6:59 PM ET other material materiality 0.90 negative item 2.02item 9.01

  Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M

  Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.

• February 6, 2026, 6:59 PM ET other material materiality 0.80 neutral item 3.01item 8.01item 9.01

  Anebulo Pharmaceuticals voluntarily delisting from Nasdaq, terminating SEC registration effective Feb 27, 2026

  Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.

• December 22, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Anebulo abandons reverse split, launches self-tender for up to 300k shares at $3.50/sh to go private

  Abandons reverse stock split (1-for-2,500 to 1-for-7,500) due to cost increase from holders splitting shares to get multiple fractional payments.

• September 29, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private

  Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).

• September 12, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Anebulo updates on going private: Board to consider sale, merger, or other alternatives

  Received inbound interest from potential financial and strategic partners after announcing going private on July 23, 2025.

• July 23, 2025, 7:59 PM ET other material materiality 0.75 negative item 8.01item 9.01

  Anebulo plans going-private via reverse split; $3.50/share for fractional shares, 91% premium

  Reverse stock split ratio range 1-for-2,500 to 1-for-7,500; stockholder vote at special meeting Aug 22, 2025.

• February 24, 2025, 6:59 PM ET regulatory materiality 0.85 negative item 1.01item 3.01item 9.01

  Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW

  Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.

• February 14, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan

  Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.

• December 23, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 5.01item 8.01item 9.01

  Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity

  Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.

• November 13, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant

  Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.

• May 15, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote

  Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.55 · Most common event other_material

4 positive 3 negative 16 neutral

source · ANEB on sec.gov